News: Simtuzumab

We provide the latest news and info on Simtuzumab

Gilead Sciences Q2 2014: All Is Good, More To Come At Medical Conferences ...
Seeking Alpha (registration)
Extremely important Pipeline data for oncology pipeline coming by year end with simtuzumab, pending data results will determine rapidity of an acquisition of MGNX and a "go/no-go" for a INCY acquisition. Congressional and Payor criticism of Sovaldi's ...

Published on Monday 28th of July 2014 09:22:00 AM Read more...

Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic
MarketWatch
Gilead is acting across a broader age spectrum in NASH treatment and should be completing enrollment soon for a Phase 2b testing of its drug simtuzumab (GS-6624). Results might be announced late 2016 or so. Gilead is looking to grow its footprint in ...

and more »

Published on Monday 28th of July 2014 09:22:00 AM Read more...

A Re-Analysis Of Gilead After Q2 Results And The Early Idelalisib Approval
Seeking Alpha (registration)
Gilead has an adventurous pipeline in cancer (simtuzumab), CV, respiratory syncytial virus, and a potential breakthrough cure for hepatitis B. This is in addition to its pipeline for hepatitis C, which is robust, and two pending approvals for single ...

and more »

Published on Monday 28th of July 2014 09:22:00 AM Read more...

Could Galectin Therapeutics Stock Be Your Next Home Run?
Motley Fool
Furthermore, the NASH market has attracted big name biotechs like Gilead Sciences (NASDAQ: GILD ) that are developing their own competing therapies. Gilead's experimental drug for NASH called "simtuzumab" is clinically more advanced than Galectin's, ...

Published on Monday 28th of July 2014 09:22:00 AM Read more...

Genfit : Galmed Pharmaceuticals précise son calendrier clinique dans la NASH
Trading Sat
devrait dévoiler en mai 2016 les résultats de son étude de phase IIB dans la NASH avec son médicament expérimental Simtuzumab. La NASH, maladie d'origine métabolique caractérisée par une dégénérescence du foie, a émergé il y a un peu moins d'un ...

and more »

Published on Monday 28th of July 2014 09:22:00 AM Read more...

Gilead Sciences-Aktie: Sovaldi sorgt für neue Umsatzrekorde, große Chancen ...
AktienCheck
... die Zulassung von Zeldig und eine sich ausweitende Pipeline von schnellen Nachfolgeprodukten wie der JAK2 Inhibitor Momelotinib sowie erste Vertreter einer neuen Therapieklasse wie das antifibrotische Simtuzumab für signifikantes Aufwärtspotenzial ...

and more »

Published on Monday 28th of July 2014 09:22:00 AM Read more...

Our Services

Do not forget to check the lastest products and auctions related to Simtuzumab as well as our free videos and podcasts.

best Simtuzumab products current Simtuzumab auctions current Simtuzumab videos listen to Simtuzumab podcasts